Press releasePRNewswire
BioMarin Pharmaceutical
BMRN · NASDAQ
$56.44+$1.77 (+3.24%)TodayMarket closed ·
Prev close $54.67
Latest news
- Press releasePRNewswire
BioMarin Appoints Cara Bauer as Chief People Officer
- Press releasePRNewswire
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
- Press releasePRNewswire
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
- Press releasePRNewswire
BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
- NewsErica Kollmann
QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target
- Press releasePRNewswire
BioMarin to Participate in Upcoming Investor Conferences
- Press releasePRNewswire
BioMarin Announces Close of the Alesta Therapeutics Acquisition
- NewsAvi Kapoor
Crude Oil Gains Over 2%; US Dallas Fed Manufacturing Index Surges In August
- NewsVandana Singh
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
- Press releasePRNewswire
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
- NewsVandana Singh
BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment
- News
BioMarin Pharmaceutical Signs Agreement To Acquire Alesta Therapeutics For $275M
- Press releasePRNewswire
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
- Press releasePRNewswire
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
- News
Biomarin Pharmaceutical Q2 Adj. EPS $1.20 Beats $0.69 Estimate, Sales $990.000M Beat $926.908M Estimate
- Press releasePRNewswire
BioMarin Reports Second Quarter 2026 Financial and Operating Results
- Press releasePRNewswire
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
- Press releasePRNewswire
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
- Press releasePRNewswire
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
- Press releasePRNewswire
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
- NewsVandana Singh
BioMarin Reveals Dwarfism Study Data, Stock Soars
- Press releasePRNewswire
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
- Press releasePRNewswire
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
- Press releaseBusiness Wire
4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of Directors
- News
Transcript: Biomarin Pharmaceutical Q1 2026 Earnings Conference Call
- Press releasePRNewswire
BioMarin Reports First Quarter 2026 Financial and Operating Results
- News
Earnings Scheduled For May 4, 2026
- Press releasePRNewswire
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
- Press releasePRNewswire
BioMarin Completes Acquisition of Amicus Therapeutics
- Press releasePRNewswire
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
- Press releasePRNewswire
BioMarin Announces Board Leadership Transition
- Press releasePRNewswire
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
- NewsVandana Singh
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
- News
BioMarin Pharmaceutical Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
- News
Earnings Summary: BioMarin Pharmaceutical Q4
- News
Biomarin Pharmaceutical Q4 Adj. EPS $0.46 Misses $0.63 Estimate, Sales $875.000M Beat $827.969M Estimate
- Press releasePRNewswire
BioMarin Announces Closing of Private Offering of Senior Notes
- Press releasePRNewswire
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
- Press releasePRNewswire
BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
- NewsAvi Kapoor
Nasdaq Surges Over 1%; Lamb Weston Shares Decline Following Q2 Results
- NewsAvi Kapoor
Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday
- News
A Look Into Biomarin Pharmaceutical Inc's Price Over Earnings
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.